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ohio-state.edu (K. Musier-Forsyth).Human immunodeﬁciency virus 1 (HIV-1) uses a host cell tRNALys,3 molecule to prime reverse tran-
scription of the viral RNA genome into double-stranded DNA prior to integration into the host gen-
ome. All three human tRNALys isoacceptors along with human lysyl-tRNA synthetase (LysRS) are
selectively packaged into HIV-1. Packaging of LysRS requires the viral Gag polyprotein and incorpo-
ration of tRNALys additionally requires the Gag-Pol precursor. A model that incorporates the known
interactions between components of the putative packaging complex is presented. The molecular
interactions that direct assembly of the tRNALys/LysRS packaging complex hold promise for the
development of new anti-viral agents.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
During the replication of human immunodeﬁciency virus 1
(HIV-1), the viral RNA genome is converted into double-stranded
proviral DNA during reverse transcription. Initiation of reverse
transcription is primed by a cellular tRNA, tRNALys,3, which is selec-
tively incorporated into the virus during its assembly. Fig. 1A
shows the components of HIV-1. The virus particle is surrounded
by membrane derived from the cell plasma membrane (PM) during
viral budding. Proteins comprising the viral structure include the
glycosylated envelope proteins and mature structural proteins
resulting from the proteolytic processing of the Gag precursor pro-
tein: matrix (MA), underlying the membrane; capsid (CA), com-
prising the wall of the core, within which are two strands of viral
RNA genome; and nucleocapsid (NC), binding to the viral RNA.chemical Societies. Published by E
virus type 1; MA, matrix
in; PR, protease; RT, reverse
uLV, murine leukemia virus;
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leiman), +1 614 688 5402 (K.
Kleiman), musier@chemistry.Additionally, three virally-encoded enzymes used during the HIV-
1 lifecycle are protease (PR), reverse transcriptase (RT), and integr-
ase (IN). PR and IN (not shown in Fig. 1A) form homodimers or
homotetramers while RT is a heterodimer. They are created upon
processing of the Gag-Pol precursor protein by viral PR.
The replication cycle of HIV-1 is shown in Fig. 1B (for review,
see [1]). Brieﬂy, HIV-1 envelope proteins bind to PM receptors of
the target cell, resulting in fusion of viral and cell membranes.
Upon its release into the cytoplasm, the CA core disassembles,
and within the resulting nucleoprotein complex, the viral RNA gen-
ome is copied into a double-stranded cDNA by RT. The tRNA pri-
mer, which is annealed to the genomic RNA primer binding site
(PBS), initiates reverse transcription [2], a complex process involv-
ing multiple strand-transfer reactions facilitated by the NC protein,
a nucleic acid chaperone [3]. The resultant double-stranded viral
DNA within the pre-integration complex is translocated into the
nucleus of the infected cell where it integrates into the host cell’s
DNA and codes for viral mRNA and proteins. Envelope protein
and regulatory proteins are coded for by spliced mRNAs, while
both Gag and Gag-Pol are translated from full-length viral RNA,
which is packaged into assembling virions where it serves as viral
genomic RNA.
The Gag and Gag-Pol proteins assemble at the PM, and during or
immediately after budding from the cell, the viral PR is activated
and cleaves the precursor proteins into the mature products shown
in Fig. 1A. A number of host cell factors are packaged during thelsevier B.V. All rights reserved.
Fig. 1. Cartoons showing the mature HIV-1 virion and HIV-1 lifecycle. (A) Schematic of the mature virus structure. MA is shown binding the virus membrane and CA forms
the core, within which NC is bound to two copies of the viral genomic RNA. Inside the core, tRNALys,3 is shown annealed to the genome. Whether free or tRNA-bound LysRS is
found in the core is not known. (B) Scheme of HIV-1 life cycle adapted from [83]. Assembly is a complex process that occurs at the PM and results in budding and maturation
of new virions. During assembly, LysRS and tRNALys are packaged by the Gag and Gag-Pol viral proteins.
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are known to participate in a channeled life cycle in mammalian
cells, and are virtually never free [4]. For this reason, the primer
tRNA cannot be selected from the microenvironment and must
be present in the mature CA core prior to initiation of reverse tran-
scription, which may initiate prior to capsid disassembly [5,6].
Thus, during virus assembly, viral genomic RNA and cellular
tRNALys isoacceptors (tRNALys,3 and tRNALys,1,2) are selectively con-
centrated at the site of assembly. A portion of the incorporated
tRNALys is annealed near the 50 end of the viral RNA to the 18-
nucleotide PBS sequence, which is perfectly complementary to
the 30-18 nucleotides of tRNALys,3. It is not known whether tRNA
annealing occurs prior to, or after, viral budding.
In lentiviruses, including HIV-1, tRNALys,3 serves as the primer
tRNA [7]. However, in avian retroviruses, tRNATrp is the primer
for all members of the avian sarcoma and leukosis virus group
examined to date [8,9], whereas tRNAPro is the common primer
for murine leukemia virus (MuLV) [10]. ‘‘Selective packaging oftRNA” refers to the increase in the percentage of the low molecular
weight RNA population representing primer tRNA in going from
the cytoplasm to the virus. For example, in avian myeloblastosis
virus (AMV), the relative concentration of tRNATrp changes from
1.4% to 32% [9]. In HIV-1 produced from COS7 cells transfected
with HIV-1 proviral DNA, both primer tRNALys,3 and the other ma-
jor tRNALys isoacceptors, tRNALys,1 and tRNALys,2, are selectively
packaged. The relative concentration of tRNALys changes from
5–6% in the cytoplasm to 50-60% in the virus [11]. tRNALys,1,2,
which differs from tRNALys,3 by 14 or 16 bases, represents two
tRNALys isoacceptors differing by 1 bp in the anticodon stem. While
not involved in functioning as a primer in HIV-1, evidence has been
found suggesting that tRNALys,1,2 may play a role in the import of
the pre-integration complex into the nucleus of the infected cell
[12]. In MuLV, selective packaging of primer tRNAPro is less dra-
matic, going from a relative cytoplasmic concentration of 5–6% to
12–24% of low molecular weight RNA [9]. The selective concentra-
tion of tRNALys is required for optimizing both annealing and infec-
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process requires an understanding of how viral RNA, tRNALys, and
viral and cellular proteins interact during HIV-1 assembly.2. Gag/Gag-Pol assembly
Gag alone is capable of forming extracellular Gag viral-like par-
ticles (VLPs), but this assembly requires RNA for its formation, and
in the absence of genomic RNA, cellular RNA can perform this func-
tion [14–17]. It is generally assumed that Gag forms multimeric
complexes at cell membranes (PM or endosomal [18]), but a pre-
membrane formation of smaller Gag complexes containing geno-
mic RNA has not been excluded. Genomic RNA is packaged through
interactions between NC protein sequences in Gag with speciﬁc
stem/loop structures at the 50 end of the genomic RNA [19,20]. A
potential role for MA, another nucleic acid binding domain, has
also been proposed [21,22]. The in vivo interaction of Gag with
Gag-Pol has also been well documented [23,24], and it is believed
that Gag-Pol is carried into the assembling particle by interaction
with CA and spacer peptide-1 (SP1) domains of Gag [25]. Cryoelec-
tron microscopy has indicated that in immature virions, Gag is
radially distributed with the N-terminal sequences within the
MA domain associated with membrane, and the C-terminal se-
quences coding for SP1-NC-spacer peptide 2 (SP2)-p6 domains
nearest the center of the virion [26,27]. Images of immature virions
have suggested that Gag molecules may be arranged in interacting
hexagonal bundles, with a Gag molecule at each vertex of the hexa-
gon [28–31], a model supported by work studying the in vitro
assembly of Gag [32]. The hexagonal order, however, appears to
be primarily at the level of CA and SP1, and the N- or C-terminal
regions of Gag are largely disordered [28–31], supporting the con-
clusion that Gag/Gag interactions occur primarily at the CA/SP1
region.3. tRNALys incorporation into HIV-1
Selective tRNALys packaging into HIV-1 occurs independent of
the genomic RNA [11]. Gag-Pol is required for packaging tRNALys
into Gag VLPs or into HIV-1 [11], and more speciﬁcally, the thumb
(TH) structural domain in RT plays an important role in the inter-
action between Gag-Pol and tRNALys [33]. Although Gag-Pol ap-
pears to play a role in stable incorporation of tRNALys, it is
believed that Gag is responsible for selecting tRNALys isoacceptors
for incorporation into VLPs. This selection is not direct but is med-
iated through speciﬁc interactions with the tRNALys binding pro-
tein, human lysyl-tRNA synthetase (LysRS) [34–37]. LysRS is
responsible for binding and aminoacylating all three tRNALys isoac-
ceptors that are found in HIV-1 particles [38]. Gag alone is sufﬁ-
cient for incorporation of LysRS into Gag VLPs [38], but as
mentioned earlier, Gag-Pol is required for tRNALys incorporation
as well [11]. Moreover, the packaging of tRNALys isoacceptors re-
quires interaction with LysRS [39] but not aminoacylation of the
tRNA [40].
The interaction of Gag with LysRS is speciﬁc, i.e., of nine amino-
acyl-tRNA synthetases (aaRSs) and three related proteins tested,
only LysRS is packaged into HIV-1 [41]. The domains critical for
the interaction have been mapped to include the so-called motif
1 domain of LysRS and the C-terminal domain of CA [34]. Deletions
that extend into either of these domains abolish the interaction
in vitro and, importantly, eliminate packaging of LysRS into Gag
VLPs [34]. Interestingly, both of these primarily helical regions
are responsible for homodimerization of their respective proteins.
An equilibrium binding constant of 310 nM was measured for the
Gag/LysRS interaction in vitro, and CA alone binds to LysRS with a
similar afﬁnity (400 nM) as full-length Gag [35,36]. Mutant Gagand LysRS that do not homodimerize still interact, suggesting that
dimerization of each protein per se is not required for the interac-
tion, even though amino acids proximal to regions involved in
forming the homodimer interfaces contribute to heterodimer for-
mation. Gel chromatography studies further support the formation
of a Gag/LysRS heterodimer in vitro. It is not known, however, if
Gag interacts in vivo with the monomeric, dimeric, or tetrameric
state of LysRS [42].
Newly-synthesized LysRS is the source of viral LysRS, which
likely interacts with Gag before entering its identiﬁed steady-state
cellular compartments (high molecular weight multisynthetase
complex (MSC), nuclei, mitochondria, cell membrane) [41,43].
Importantly, siRNA knockdown of newly synthesized LysRS (80%)
results in similarly reduced levels of tRNALys packaging, tRNALys,3
priming by reverse transcriptase, and viral infectivity [43]. It has
also been reported that mitochondrial LysRS (mLysRS) is a source
of viral LysRS [37,44]. In human cells, cytoplasmic LysRS (cLysRS)
and mLysRS are encoded from the same gene by means of alternate
splicing. The two LysRS species share 576 identical amino acids,
but mLysRS has a different N-terminus of 49 amino acids that con-
tains a putative mitochondrial targeting sequence [45]. In HIV-1
produced from U937 cells, antibodies directed to full-length LysRS
detected full-length and truncated species, while antibodies spe-
ciﬁc for the unique N-termini of cLysRS and mLysRS were only able
to detect mLysRS. These data support the conclusion that mLysRS
is a source of viral LysRS [37]. However, the conclusion that
mLysRS is the sole source of viral LysRS contradicts several reports
in which expression of exogenous cLysRS in transfected HIV-1 pro-
ducing cells results in cLysRS incorporation [13,34,40,46]. This
enhancement in LysRS packaging is associated with increases in
tRNALys packaging, tRNALys,3 annealing, and viral infectivity [13].
We suggest that the inability to detect cLysRS in virions using anti-
bodies directed to the N-terminus may be associated with the
lability of the N-terminus of cLysRS [38]. In vitro mapping studies
also support the possibility that both forms of LysRS are possible
sources for viral packaged LysRS, as the region of interaction with
Gag is the motif 1 dimer interface present in both mitochondrial
and cytoplasmic forms of the synthetase [35,36].4. Formation of the tRNALys packaging complex
While tRNALys is targeted for incorporation into HIV-1 by a spe-
ciﬁc interaction of HIV-1 Gag with LysRS, RT sequences within Gag-
Pol must also be present, or LysRS will be packaged without
tRNALys [33,38]. Predicted relationships within the putative
tRNALys packaging complex are schematically shown in Fig. 2,
along with the mature protein sequences coded for by the Gag
and Gag-Pol precursors. In Fig. 2, a Gag/Gag-Pol/viral RNA complex
interacts with a tRNALys,3/LysRS complex, with Gag binding specif-
ically to LysRS, and tRNALys,3 binding to RT domain in Gag-Pol. In
the virus, tRNALys,3 is uncharged (i.e., has a free 30 hydroxyl group
on the ribose of the terminal adenosine) [47], and must be in this
state in order to act as a primer for RT. It is not known if tRNALys,3
is uncharged at the time of these interactions, or if the interaction
of Gag with LysRS facilitates deacylation and release of tRNALys
from the synthetase. In vitro studies have shown that the presence
of Gag inhibits aminoacylation by human LysRS but does not pro-
mote deacylation of Lys-tRNALys (R. Kennedy, M. Hong, and K. Mu-
sier-Forsyth, unpublished data).
Based on the following data, we predict that the Gag/Gag-Pol
ratio in the tRNALys packaging complex is lower than the ratio pres-
ent in the budding virion. When transfected 293T cells producing
HIV-1 are pulsed for 10 min with 35S-Cys/Met, 15% of newly-syn-
thesized Gag and >95% of newly-synthesized Gag-Pol are found
associated with membrane domains enriched in lipid rafts [48], a
Fig. 2. Schematic illustration of the interactions that may occur within the LysRS/tRNALys packaging complex. A single copy of each molecule is shown for simplicity. The Gag
protein interacts with LysRS via the CA C-terminal domain (CTD) and Pol interactions (RT domain) with LysRS have also been reported to play a role in vivo. The RT domain of
Pol also interacts with tRNALys and may help to position tRNALys,3 for annealing onto the PBS. CA-CTD/CA-CTD interactions occur between Gag proteins and between Gag and
Gag-Pol. The highly basic NC protein contacts the viral RNA packaging signal, and additional contacts between the viral RNA and LysRS may also occur. The RNA secondary
structure proximal to the PBS is taken from [84].
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[49,50]. The Gag and Gag-Pol molecules at this membrane domain
are presumably interacting since the movement of Gag-Pol to
membrane requires association with Gag, which is driven by the
interaction between homologous Gag sequences within Gag and
Gag-Pol [23,51]. Since the ratio of synthesis of Gag/Gag-Pol in cells
has been estimated to be approximately 20:1 [52], the ratio of
newly-synthesized Gag:Gag-Pol at lipid raft domains would be
3:1—much lower than the Gag:Gag-Pol ratio found in immature
virions. It was observed that during a 30-min chase period, more
Gag molecules moved towards lipid raft-enriched membrane
[48], implying that the tRNALys,3 packaging/annealing complex
may represent a very early assembly intermediate to which more
Gag is later added. However, this assembly intermediate has not
been directly detected.
In such an assembly intermediate, Gag-Pol may be present as a
dimer, which is required for later Gag and Gag-Pol processing [53].
Gag and Gag-Pol would be present in a 3:1 ratio. LysRS may be
present as a monomer since monomeric LysRS has been shown
to interact with monomeric Gag in vitro [36]. However, as men-
tioned earlier the oligomeric state of LysRS upon interaction with
Gag in vivo is not known. Gag-Pol may adopt a conformation to
interact with Gag, reminiscent of the intermolecular interaction
between Pol and Gag in human foamy viruses [54]. Expression of
HIV-1 Pol and Gag from separate plasmids in 293T cells results
in the incorporation of Pol into Gag VLPs, and Pol can replace
Gag-Pol in facilitating the selective incorporation of tRNALys into
the Gag VLPs [55]. Recent reports also indicate that RT sequences
alone can be incorporated into Gag VLPs, with apparent interac-
tions occurring between MA and p6 sequences in Gag and the TH
domain in RT [56,57].
The association of Gag-Pol with Gag is most likely driven by an
interaction between homologous Gag sequences in both molecules,
and the model in Fig. 2 shows the additional interactions that have
been proposed to date. The model shows tRNALys,3 bound to TH in
RT, which is based both on in vitro studies on the interaction of
puriﬁed HIV-1 RT with tRNALys,3 [58,59], and in vivo studies on
the effect of C-terminal deletions in Gag-Pol upon tRNALys,3 incor-poration into HIV-1 [33,60]. The model also shows the 50 region of
viral genomic RNA. HIV-1 genomic RNA is packaged into the virus
through interactions between NC sequences in Gag and speciﬁc
stem/loop structures at the 50 end of the genomic RNA [19,20].
The PBS is located within 100 nucleotides upstream of these se-
quences. Additional interactions between LysRS and genomic
RNA proximal to the PBS may also facilitate tRNA targeting and
placement (C. Jones, J. Saadatmand, L. Kleiman, and K. Musier-For-
syth, unpublished data). During viral maturation, the ﬁrst PR cleav-
age is between SP1 and NCp7 [61]. An interaction between Pol and
Gag could insure that Pol is retained in the partially closed budding
particle if proteolytic cleavage initiates during assembly. The fact
that p6 is required for the interaction of Gag with Pol is of interest
in this context since it has been reported that the deletion of p6
from Gag resulted in a lower concentration of Pol products in PR-
positive HIV-1, but no change in Gag-Pol incorporation in PR-neg-
ative viruses [62].
The model in Fig. 2 suggests that an interaction between LysRS
and Pol sequences might facilitate formation of the complex. In
support of this model, an interaction between LysRS and the con-
nection domain (CD)/RNaseH domains in RT has been reported
[57]. LysRS and mature RT do not interact in vitro (T. Stello, L. Klei-
man, and K. Musier-Forsyth, unpublished data), and thus, this
interaction may only occur in the context of Pol or may be indirect,
and the function of this interaction is not yet clear. Since C-termi-
nal deletions of Gag-Pol that include the RT CD do not inhibit
tRNALys,3 packaging [60], the LysRS/RT interaction is not involved
in facilitating tRNALys,3 packaging. On the other hand, virions in
which Gag-Pol is C-terminally deleted through the RT CD do not
contain annealed tRNALys,3. This could mean that a Gag/LysRS/RT
interaction may be involved in conformational changes facilitating
movement of tRNALys,3 towards the PBS.
In summary, based on the current estimates of 2500 Gag mol-
ecules in immature HIV-1 particles [31,63,64], we estimate that
within the tRNALys packaging complex, an early assembly interme-
diate, there may be approximately 300 molecules of Gag, 100 mol-
ecules of Gag-Pol, 25 molecules of LysRS [65], and 20–25 molecules
of tRNALys [47] in addition to viral genomic RNA. Our model in
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mal to the Gag molecule(s) that are chaperoning tRNA annealing
(see below), in order to facilitate transfer of tRNALys,3 from LysRS
to the PBS, via RT. Ongoing studies are aimed at understanding
whether additional interactions between LysRS and genomic RNA
help to target this complex to the PBS region.
5. When does annealing of tRNALys,3 to viral RNA occur?
Previous in vitro studies have shown HIV-1 NC to be a very
effective nucleic acid chaperone protein that facilitates nucleic acid
remodeling events throughout the reverse transcription process
[66]. Although NC can efﬁciently catalyze tRNALys,3 annealing onto
the PBS in vitro [67], in viruses lacking active PR, tRNA annealing to
the PBS still occurs, suggesting that the precursor protein Gag may
act as a NA chaperone and facilitate this process in vivo [68,69]. In-
deed, GagDp6, which lacks the C-terminal p6 domain, and other
assembly-competent Gag variants have been demonstrated to
facilitate tRNA annealing and genome dimerization in vitro
[70,71]. New studies also show that Gag’s chaperone activity is
stimulated upon interacting with inositol phosphates in the PM
(C. Jones, S. Datta, A. Rein, I. Rouzina, and K. Musier-Forsyth,
submitted).
While it has been demonstrated that the selective packaging of
primer tRNALys,3 into HIV-1 is correlated with achieving optimal
annealing of tRNALys,3 and infectivity of the HIV-1 population
[13], it is not known whether selective packaging of tRNALys,3 is re-
quired for annealing. That is, selective packaging of tRNALys,3 into
the virus may be due to a higher local concentration of tRNA at
the site of viral assembly, where annealing may take place prior
to viral budding. It has been shown that tRNALys,3 annealed
in vivo or in vitro to viral RNA by Gag has a reduced ability to ini-
tiate reverse transcription [72] and results in a less stably annealed
state relative to tRNALys,3 annealed by NC [69]. This reduced ability
of Gag-annealed tRNALys,3 to function as a primer for reverse tran-
scription can be rescued by a transient exposure of total viral RNA
isolated from PR-negative virions to NC. Taken together, these data
suggest that tRNALys,3 annealing may be a two-step process, involv-
ing an initial Gag-facilitated annealing at the site of viral assembly,
followed by a re-annealing by NC after protein processing. Alterna-
tively, NC may chaperone the refolding of viral RNA into an alter-
native structure to the one stabilized by Gag. Evidence for an
RNA structural change that could govern RT initiation has been de-
scribed [73].
6. Future prospects
Understanding the mechanism by which the tRNA packaging
complex is targeted to the 50 region of the genomic RNA, and prob-
ing the timing of tRNA annealing in the viral lifecycle are just two
of the open questions currently under investigation. Gag interacts
with viral genomic RNA and the PM, but Gag’s interactions with
other host cell factors such as LysRS, ABCE1, cyclophilin A,
Tsg101, and ALIX are also critical to virus infectivity [38,74–77].
Interaction with so many cellular factors may be achieved by dis-
tinct pools of Gag, each interacting with separate essential factors
and ultimately mixing during assembly at the PM. How newly syn-
thesized LysRS is diverted from its normal function in translation
to interact with HIV components is not known, but one of the cel-
lular pools of Gag presumably recruits LysRS from its normal role
in translation to aid virus replication. aaRSs have been shown to
function in a wide array of cellular processes that are distinct from
aminoacylation [78]. The expanded functions of synthetases and
other components of the MSC have been shown to be regulated
at the level of posttranslational modiﬁcation. For example, in thecase of human glutamyl-prolyl tRNA synthetase (EPRS), phosphor-
ylation is required for its release from the MSC and for formation of
the heterotetrameric c-interferon-activated inhibitor of translation
(GAIT) complex [79–81]. Recently, speciﬁc phosphorylation of hu-
man LysRS has been shown to regulate Ap4A production in re-
sponse to immunological challenge [82]. Phosphorylation results
in release of LysRS from the MSC, enhanced Ap4A synthesis, and
transcriptional activation via interaction with MITF [82]. While
we do not yet know the phosphorylation state of LysRS that is
incorporated into HIV, one intriguing possibility is that HIV infec-
tion triggers posttranslational modiﬁcations that modulate the
oligomerization state of LysRS and/or LysRS–protein interactions.
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